The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2016

Filed:

Nov. 30, 2012
Applicants:

Reflexion Pharmaceuticals, San Francisco, CA (US);

The Governing Council of the University of Toronto, Toronto, CA;

Inventors:

Dana Ault-Riche, San Francisco, CA (US);

Maruti Uppalapati, Toronto, CA;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/11 (2006.01); G01N 33/68 (2006.01); G01N 33/569 (2006.01); C07K 14/005 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/11 (2013.01); C07K 14/005 (2013.01); G01N 33/56983 (2013.01); G01N 33/68 (2013.01); G01N 33/6845 (2013.01); A61K 38/00 (2013.01); C12N 2760/16122 (2013.01); G01N 2333/11 (2013.01);
Abstract

GB1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds. Also provided are hemagglutinin mimics and fragments and methods of using the same, including methods of screening for GB1 peptidic compounds and methods of using conjugates the mimics as influenza A vaccines. Aspects of the invention include methods of screening libraries of L-peptidic compounds for specific binding to a D-peptidic hemagglutinin target protein. Once a L-peptidic compound has been identified that specifically binds to the D-peptidic hemagglutinin target protein, the D-enantiomer of the selected L-peptidic compound may be produced. In some embodiments, the D-enantiomer of the selected L-peptidic compound binds to, and in some instances, neutralizes influenza virus particles.


Find Patent Forward Citations

Loading…